Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by ready2go1on Jun 02, 2010 5:42pm
270 Views
Post# 17152057

RE: Now That's Liquidity...800 shares traded

RE: Now That's Liquidity...800 shares tradedIt has been since 6/20/08 that it traded less shares, 600. I keep feeling like someone is playing games with the news we have had out and the share price trading in a very narrow range with little to no volume.
     I can understand that GPRO just wants to get their study in front of the FDA and not advertise that the marker can do so much more than they are submitting for.
     I no longer get market depth and it could be that there are not any ask orders and someone looking to pick up a position would run this thing up, so they just sit on the sidelines or hold tight with their bid.
    What will ASCO bring?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities